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Abstract
Purpose The aim of this study was to compare the effects
of fibrates and omega-3 fatty acids on lymphocyte secretory
function and systemic inflammation in patients with
isolated hypertriglyceridemia.
Methods The study included 107 patients with isolated
hypertriglyceridemia who received bezafibrate (200 mg
twice daily), omega-3 fatty acids (1 g twice daily) or
placebo for 12 weeks. The lipid profile, fasting and 2-h post-
glucose load plasma glucose levels, homeostasis model
assessment index (HOMA), plasma high-sensitivity C-
reactive protein (hsCRP) levels and lymphocyte release of
interleukin-2, interferon-γ and tumor necrosis factor-α were
assessed at baseline, on the day of randomization, and after 4
and 12 weeks of treatment.
Results Both bezafibrate and omega-3 fatty acids reduced
plasma triglyceride levels. Bezafibrate additionally decreased
total and low-density lipoprotein-cholesterol levels and the
HOMA and insignificantly decreased post-glucose load
plasma glucose, as well as increased high-density
lipoprotein-cholesterol. Bezafibrate treatment was associated
with a reduction in lymphocyte release of interleukin-2,
interferon-γ and tumor necrosis factor-α, which was accom-
panied by a reduction in plasma hsCRP levels. Omega-3 fatty
acid did not significantly reduce lymphocyte cytokine release
and plasma hsCRP. The anti-inflammatory effects of both
drugs did notcorrelate with theiraction on plasma lipids, butin
thecaseoftheformertheeffectwasrelatedtotheimprovement
in insulin sensitivity.
Conclusion Our results indicate that bezafibrate is superior
to omega-3 fatty acid in inhibiting systemic inflammation
and lymphocyte secretory function.
Keywords Bezafibrate.Omega-3 fatty acids.Isolated
hypertriglyceridemia.Lymphocytes.Proinflammatory
cytokines.Low-grade inflammation
Introduction
Elevated triglyceride levels are modestly associated with
the earlier development and accelerated progression of
coronary artery disease [1]. In the Copenhagen Male Study
[2], the Baltimore Observational Long Term Study [3] and
the Bezafibrate Infarction Prevention study [4], which
involved middle-aged and elderly men [2], subjects who
underwent diagnostic coronary arteriography [3]a n d
patients with coronary artery disease [4], respectively, the
presence of hypertriglyceridemia was associated with an
increased risk of cardiovascular morbidity and mortality. In
a meta-analysis performed by Austin et al. [5], which
included the results of 21 studies, each 90 mg/dL (1 mmol/L)
increase in plasma triglycerides was associated with a 32%
increase in coronary artery disease events in men and a 76%
increase in coronary artery disease events in women.
However, adjustment for established coronary risk factors,
especially for high-density lipoprotein (HDL) cholesterol,
substantially attenuated the magnitude of the association
between raised circulating triglyceride levels and increased
coronary artery disease risk [6]. Moreover, because hyper-
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metabolic syndrome, increased cholesterol levels, disturbed
hemostasis and inflammation, some researchers assume that
elevated triglyceride levels may be only a non-causal
biomarker of future cardiovascular risk [7].
Activated T lymphocytes are present in all stages of
human atherosclerotic lesion development, which implies
their involvement in atherogenesis [8]. The major class of T
cells found in the plaque, namely CD4+ helper cells,
recognizes antigens associated with class II major histo-
compatibility complex (MHC) molecules, and mounts T
helper cell type 1 responses with the secretion of
proinflammatory cytokines, thus contributing to local
inflammation and growth of the plaque [9]. Activated T
lymphocytes stimulate macrophages of atherosclerotic
lesions to produce metalloproteinases, which promote
plaque instability and further implicate an immune response
[8, 9]. Therefore, inhibiting lymphocyte function may bring
benefits to subjects with disturbed lipid metabolism,
preventing or delaying the development of atherosclerosis
and its complications.
To the best of our knowledge, no previous study has
investigated the effect of any hypolipidemic agents on
lymphocyte secretory function in this type of dyslipidemia.
Although lymphocytes are involved in the pleiotropic
effects of statins [10–12], these agents are not routinely
used in subjects with isolated hypertriglyceridemia [7]. In
turn, as our observations show, the strength of action of
peroxisome proliferator-activated receptor-alpha (PPARα)
activators on lymphocyte cytokine release depends on the
underlying disorder. The lymphocyte-suppressing effect of
fibrates was evident in impaired glucose tolerance patients,
absent in impaired fasting glucose individuals [14] and
weak in mixed dyslipidemic subjects [10]. Therefore, the
aim of the study reported here was to compare the effects of
bezafibrate and omega-3 fatty acids, two different treatment
options for hypertriglyceridemia, on the lymphocyte secre-
tory function in terms of their action on systemic
inflammation in subjects with isolated elevation of plasma
triglyceride levels. Interleukin (IL-2), interferon (IFN)-γ
and tumor necrosis factor-alpha (TNF-α), all of which were
assessed in our study, belong to the most important
cytokines secreted by T cells and are regarded as relevant
cardiovascular risk factors determining the risk of acceler-
ated progression of atherosclerosis and the development of its
complications [13, 15]. To determine whether their action on
lymphocyte cytokine release is associated with a global anti-
inflammatory effect, we measured high-sensitivity C-reactive
protein (hsCRP) plasma levels, a highly sensitive marker of
low-grade inflammation that has been shown in multiple
prospective epidemiological studies to predict incident
myocardial infarction, stroke, peripheral arterial disease, and
sudden cardiac death [16, 17].
Methods
Subjects
Patients with recently diagnosed andpreviously untreated lipid
metabolism abnormalities were eligible for inclusion in the
study if they met the criteria of primary isolated hyper-
triglyceridemia [triglycerides between 200 mg/dL (2.3 mmol/
L) and500mg/dL(5.7mmol/L); totalcholesterol <200mg/dL
(5.2 mmol/L); LDL-cholesterol <130 mg/dL (3.4 mmol/L)].
The exclusion criteria were: age >70 or <35 years;
diabetes mellitus; any acute and chronic inflammatory
processes; congestive heart failure; unstable coronary artery
disease; myocardial infarction or stroke within 6 months
preceding the study; moderate or severe arterial hyperten-
sion (grade 2 or 3 hypertension according to the European
Society of Hypertension and European Society of Cardiology
guidelines: systolic blood pressure ≥160 mm Hg and/or
diastolic blood pressure ≥100 mm Hg); impaired renal or
hepatic function; concomitant treatment with other agents
known either to affect plasma lipid levels or to interact with
fibrates or omega-3 fatty acids; treatment with drugs that may
affect inflammatory processes in the vascular wall (including
glucocorticosteroids, nonsteroid anti-inflammatory drugs,
calcium channel blockers, angiotensin converting enzyme
inhibitorsorangiotensinIIreceptorblockers) within3months
preceding the study; ongoing hormonal replacement therapy
or oral contraception; and poor patient compliance.
Study design
The study was approved by the Bioethical Committee of
the Medical University of Silesia. Written informed consent
was obtained from all study participants, and the study was
performed according to the Declaration of Helsinki. All
participants were informed about the benefits of a healthy
diet and recommended to stop smoking, cease alcohol
consumption and increase their physical activity to at least
30 min of moderate physical activity per day. Four weeks
later, hypertriglyceridemic patients were randomized to
bezafibrate (400 mg daily, n=37), omega-3 fatty acids
(2 g daily, n=37) or placebo (n=33). Omega-3 fatty acids
were administered in a form of a purified preparation
consisting mainly of eicosapentaenoic acid (EPA) (465 mg)
and docosahexaenoic acid (DHA) (375 mg). Both drugs
and placebo were administered twice daily in two equal
doses. On the basis of the value of the homeostasis model
assessment index (HOMA), each treatment group was
divided into two subgroups comprising patients with
normal or disturbed insulin sensitivity, respectively. Normal
insulin sensitivity was arbitrary defined as a HOMA <2.0.
If this value was exceeded, the patient was diagnosed as
being insulin-resistant.
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fatty acid-induced adverse effects was performed every
2 weeks. Compliance was investigated at each visit by
tablet counts and was considered to be satisfactory when
the number of tablets taken by a patient ranged from 90 to
100%.
The primary study objective was to evaluate the
lymphocyte-suppressing and systemic anti-inflammatory
effects of bezafibrate and omega-3 fatty acids using a panel
of inflammation markers: IL-2, IFN-γ,T N F - α and hsCRP.
Laboratory assays
The plasma levels of lipids, glucose and hsCRP and
lymphocyte cytokine release were determined at baseline,
on the day of randomization, and after 4 and 12 weeks of
therapy. Venous blood samples were drawn from the
antecubial vein after a 12-h overnight fast, in a quiet,
temperature-controlled room (24-25°C) between 0800 and
0900 hours (to avoid possible circadian fluctuations in the
parameters studied). All blood samples were taken between
0800 and 0900 hours. All assays were carried out in duplicate
to minimize analytical errors. The plasma lipid levels (total
cholesterol, LDL-cholesterol, HDL-cholesterol and triglycer-
ides) were determined colorimetrically using reagents pur-
chased from bioMerieux (Marcy l’Etoile, France). LDL levels
were measured directly. Plasma glucose concentrations were
analyzed by a glucose oxidase method (Beckman, Palo Alto,
CA). Plasma insulin was measured using a commercial
radioimmunoassay kit (Linco Research, St Charles, MO).
The HOMA was calculated from the following equation:
fasting serum glucose (mmol/L) × fasting insulin level
(μU/mL)/22.5. The value of insulin used in this equation
was the mean value of its concentrations in three different
blood samples taken at 5-min intervals. Plasma levels of CRP
were measured using a high-sensitivity monoclonal antibody
assay (MP Biomedicals, Orangeburg, NY). The lower limit of
sensitivity of this method was 0.1 mg/L, while the intra-assay
coefficients of variation were 4.3%. T cells were cultured in
triplicate as described earlier [10]. The release of IL-2, IFN-γ
and TNF-α by phytohemagglutinin-stimulated lymphocytes
was measured using commercially available enzyme immu-
noassay methods (R&D Systems, Minneapolis, MN). To
avoid the freeze-thawing effect, each assay was performed on
a single sample aliquot. The minimum detectable levels for
IL-2, IFN-γ and TNF-α were 8, 15 and 4.4 pg/ml,
respectively; the respective intra-assay coefficients ofvariation
were 3.8, 5.5 and 4.6%.
Power calculations
The sample size required for the study was calculated using
Sample Power software (SPSS ver. 2.0; SPSS, Chicago, IL)
based on data from our previous studies, assuming 80%
power and a significance (α) level of 0.05. According to the
statistical power calculation, at least 90 patients would need
to be randomized to detect a 20% difference in all
components of the primary endpoint between pre- and
posttreatment values within the same treatment group.
Taking into account possible drop-outs and possible
estimation and measurement inaccuracies, the number of
participants (not counting the control group) was therefore
increased to 107 patients.
Statistical analysis
The statistical analysis was performed using GraphPad
Prism ver. 2.01 software (GraphPad Software, San
Diego, CA) and Statistica 6.1 (StatSoft, Tulsa, OK). In
all analyses, a p value of <0.05 was considered to be
statistically significant. The chi-squared test was used for
all qualitative variables. Comparisons between the groups
were performed using one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparison
test (lipid profile, glucose), or with the Kruskall–Wallis
test followed by the Mann–Whitney U test (HOMA,
hsCRP, cytokines). Student’sp a i r e dt test (lipid profile
and plasma glucose) or the Wilcoxon test (HOMA, hsCRP
and cytokines) were applied to compare pre-, inter- and
posttreatment data within the same group. Correlations
were studied using Kendall"st a ut e s t .
Results
Baseline characteristics
Main baseline characteristics of the included patients are
summarized in Table 1. All treatment groups were well
matched for general characteristics.
Adverse effects
In two patients treated with bezafibrate, therapy was
discontinued prematurely because of headaches, nausea
and abdominal pains. One subject receiving omega-3
fatty acids dropped out because of poor compliance with
the study protocol. Two subjects randomized to omega-3
fatty acids discontinued medication because of nausea
and vomiting. One patient who was randomized to
placebo reported dizziness and declined to participate
further in the study. No other serious adverse events
occurred during the study. Baseline characteristics of the
six subjects who left the study did not differ from those
of the 101 patients who completed the study and were
included in the final analyses.
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A 4-week run-in period of non-pharmacological treatment
did not affect plasma lipids, fasting and post-challenge
plasma glucose, HOMA, hsCRP and lymphocyte release of
IL-2, IFN-γ and TNF-α (Tables 2 and 3).
Placebo-treated group
The 12-week placebo treatment had no effect on the lipid
profile, glucose metabolism markers, hsCRP and cytokine
release (Tables 2 and 3).
Omega-3 fatty acid-treated group
In hypertriglyceridemic subjects, omega-3 fatty acids
reduced plasma triglycerides by 23.1% (p<0.05) after
4 weeks of treatment and by 31.2% (p<0.01) after
12 weeks. Total, LDL- and HDL-cholesterol, fasting and
post-challenge plasma glucose and the HOMA remained at
a similar level throughout the study (Table 2). Moreover,
omega-3 fatty acids insignificantly reduced IL-2 release by
16.4 (p=0.088) and 18.2% (p=0.078), IFN-γ release by
17.8 (p=0.084) and 19.0% (p=0.074) and TNF-α release
by 19.0 (p=0.068) and 19.4% (p=0.065), as well as plasma
hsCRP levels by 16.1 (p=0.090) and 19.4% (p=0.062)
after 4 and 12 weeks of treatment, respectively. There were
no differences between the effect of omega-3 fatty acids on
lymphocyte cytokine release and plasma hsCRP between 4
and 12 weeks of treatment (Table 3).
There were no differences in the effect of omega-3 fatty
acidsonthe HOMA,plasmahsCRPandlymphocytecytokine
release between “insulin-sensitive” and “insulin-resistant”
patients (Table 4).
Bezafibrate-treated group
Bezafibrate treatment reduced plasma triglycerides by
35.8% (p<0.001) and 37.8 (p<0.001), total cholesterol by
15.3 (p<0.05) and 15.6% (p<0.05) and LDL-cholesterol by
13.1 (p<0.05) and 14.3% (p<0.05), as well as increased
HDL-cholesterol by 20.5 (p<0.01) and 22.9% (p<0.01)
after 4 and 12 weeks of treatment, respectively. The
treatment also resulted in a reduction in the HOMA by
21.1% (p<0.05) after 4 weeks and by 50.0% (p<0.001)
after 12 weeks of administration. Bezafibrate-induced
changes in the HOMA were more evident at the end of
the study than after 4 weeks of treatment. Bezafibrate
treatment of isolated hypertriglyceridemic subjects did not
change the fasting plasma glucose level, but it did reduce
the 2-h post-challenge plasma glucose level, albeit non-
signficantly (after 4 weeks of treatment, by 8.8%, p=0.092;
at end of study: by 10.2%, p=0.074 (Table 2).
After 4 weeks of bezafibrate administration to hyper-
triglyceridemic subjects, the drug reduced IL-2 release by
28.8% (p<0.01), IFN-γ by 24.5% (p<0.05) and TNF-α by
Characteristics Treatment groups
Placebo Omega-3 fatty acids Bezafibrate
Number of patients 32 34 35
Age (years) 52.5±3.1 53.1±3.5 53.7±3.2
Men/women 21/11 22/12 23/12
Body mass index (kg/m
2) 28.3±2.4 28.6±2.8 28.8±2.6
Smokers (%) 31.3 35.3 31.4
Mild hypertension (%) 25.0 26.5 28.6
Stable coronary artery disease (%) 28.1 26.5 22.8
Carotid artery atherosclerosis (%) 25.0 23.5 25.7
Total cholesterol (mg/dl) 168.9±7.3 170.2±8.1 169.8±8.0
LDL-cholesterol (mg/dl) 101.3±4.1 100.9±6.0 102.3±3.7
HDL-cholesterol (mg/dl) 37.7±1.2 37.1±1.5 37.3±1.4
Triglycerides (mg/dl) 380.2±36.4 378.2±39.2 371.2±35.1
Fasting glucose (mg/dl) 96.0±2.9 95.9±2.6 96.4±2.4
2-h post-glucose load plasma glucose (mg/dl) 137.0±8.7 136.9±5.8 138.0±6.2
HOMA ratio 3.7±0.2 3.5±0.4 3.8±0.5
hsCRP (mg/L) 3.1±0.3 3.3±0.5 3.3±0.4
Interleukin-2 release (ng/mL) 5.5±0.4 5.9±0.8 5.7±0.6
Interferon-γ release (ng/mL) 62.2±7.1 65.2±8.0 64.1±8.2
TNF-α release (pg/mL) 400.1±42.5 398.1±45.2 402.3±38.5
Table 1 Baseline characteristics
of patients
a
LDL, Low-density lipoprotein;
HDL, high-density lipoprotein;
HOMA, homeostasis model
assessment index; hsCRP,
high-sensitivity C-reactive pro-
tein; TNF, tumor necrosis factor
Where appropriate, data are
given as the mean±standard
deviation (SD)
aOnly data of patients who com-
pleted the study were included in
the final analyses
1112 Eur J Clin Pharmacol (2011) 67:1109–111723.6% (p<0.05) as well as decreased plasma hsCRP by
31.3% (p<0.001). At the end of the study, IL-2 release,
IFN-γ release, TNF-α release and plasma hsCRP, when
compared to baseline, decreased by 52.5 (p<0.001), 46.5
(p<0.001), 38.5 (p<0.001) and 59.4% (p<0.001), respec-
tively. Bezafibrate-induced changes in plasma hsCRP and
lymphocyte cytokine release were more pronounced after
12 weeks than after 4 weeks of therapy (Table 3).
Bezafibrate affected the HOMA, plasma hsCRP and
lymphocyte cytokine release more strongly in “insulin-
resistant” than “insulin-sensitive” patients (Table 4).
Correlations
At entry, there was a correlation between plasma hsCRP
and lymphocyte secretory function (r=0.48–0.58, p<
0.001), as well as between cytokine release or hsCRP and
HOMA(r=0.50–0.62, p<0.001). The effect of hypolipidemic
agents on cytokine release and hsCRP did not correlate with
their action on plasma triglycerides (bezafibrate-treated
patients: r=0.24 between ΔIL-2 and Δtriglycerides, r =0.32
between ΔIFN-γ and Δtriglycerides, r=0.35 between ΔTNF-
α and Δtriglycerides, r=0.26 between ΔhsCRP and Δtrigly-
Assay results Treatment groups
Placebo Omega-3 fatty acids Bezafibrate
Total cholesterol (mg/dL)
Baseline 168.9±7.3 170.2±8.1 169.8±8.0
Before randomization 166.1±6.7 169.2±4.9 168.3±4.9
After 4 weeks of treatment 164.4±6.9 173.6±6.8 142.5±5.2
#*^
After 12 weeks of treatment 168.5±8.7 174.4±6.8 142.1±5.1
#*^
LDL-cholesterol (mg/dL)
Baseline 101.3±4.1 100.9±6.0 102.3±3.7
Before randomization 100.3±4.2 99.5±5.7 102.1±3.5
After 4 weeks of treatment 99.8±3.9 102.3±4.6 88.7±4.8
#*^
After 12 weeks of treatment 102.5±4.2 104.2±5.0 87.5±5.0
#*^
HDL-cholesterol (mg/dL)
Baseline 37.7±1.2 37.1±1.5 37.3±1.4
Before randomization 37.5±1.9 38.2±1.4 37.5±1.5
After 4 weeks of treatment 38.0±1.5 39.3±1.7 45.2±1.7
##*^
After 12 weeks of treatment 37.8±1.4 39.7±2.0 46.1±1.6
##**^
Triglycerides (mg/dL)
Baseline 380.2±36.4 378.2±39.2 371.2±35.1
Before randomization 366.2±30.3 348.8±38.1 351.2±31.8
After 4 weeks of treatment 346.5±43.2 268.1±28.0
# 225.3±27.2
###***
After 12 weeks of treatment 344.1±46.5 240.1±29.7
##** 218.2±28.3
###***
Fasting glucose (mg/dL)
Baseline 96.0±2.9 95.9±2.6 96.4±2.4
Before randomization 94.9±3.5 94.6±3.1 96.0±3.2
After 4 weeks of treatment 96.5±3.0 94.0±2.9 92.4±2.9
After 12 weeks of treatment 95.1±2.8 95.1±3.7 91.8±3.5
2-h post-glucose load plasma glucose (mg/dL)
Baseline 137.0±8.7 136.9±5.8 138.0±6.2
Before randomization 138.2±8.0 131.1±7.0 137.2±5.3
After 4 weeks of treatment 138.8±8.3 137.9±6.8 125.1±4.9
After 12 weeks of treatment 136.5±7.5 140.9±6.5 123.2±5.5^
HOMA
Baseline 3.7±0.2 3.5±0.4 3.8±0.5
Before randomization 3.6±0.4 3.4±0.3 3.8±0.4
After 4 weeks of treatment 3.4±0.3 3.7±0.4 3.0±0.3
#^
After 12 weeks of treatment 3.5±0.3 3.8±0.3 1.9±0.2
###***^^^
$$
Table 2 The effect of bezafi-
brate and omega-3 fatty acids on
the lipid profile and glucose
homeostasis markers in
hypertriglycericemic patients
a
Significance levels:
#p<0.05,
##p<0.01,
###p<0.001 vs.
respective value before random-
ization. *p<0.05, **p<0.01,
***p<0.001 vs. placebo-treated
patients. ^p<0.05, ^^^p<0.001
vs. omega-3 fatty acid-treated
patients.
$$p<0.01 vs.
respective value after 4 weeks
of treatment
Data are given as the mean±SD.
a Only data of patients who
completed the study were
included in the final analyses
Eur J Clin Pharmacol (2011) 67:1109–1117 1113cerides—all non-significant; omega-3 fatty acid-treated
patients: r=0.31 between ΔIL-2 and Δtriglycerides, r=0.28
between ΔIFN-γ and Δtriglycerides, r=0.34between ΔTNF-
α and Δtriglycerides, r=0.29 between ΔhsCRP and Δtrigly-
cerides—all non-significant) nor with the action of these
agents on the remaining lipid/lipoprotein fractions (bezafibrate-
treated patients: r=0.04–0.22, all non-significant; omega-3
fatty acid-treated patients: r=0.06–0.24, all non-significant).
In subjects treated with bezafibrate, the effect of this drug on
cytokine release correlated with its action on hsCRP (r=0.47–
0.61, p<0.001). Moreover, in this group of patients,
bezafibrate-induced changes in hsCRP and cytokine release
correlated with the changes in the HOMA (r=0.51–0.58, p<
0.001).
Discussion
Our study is the first to show that bezafibrate is able to
inhibit lymphocyte release of proinflammatory cytokines,
while the effect of omega-3 fatty acids appears to be much
less pronounced. The anti-inflammatory actions of the
former drug observed in our study, which explain the
reduction in whole blood TNF-α and IL-6 production in
bezafibrate-treated hypertiglyceridemic subjects [18, 19],
are in line with results from large clinical trials. Bezafibrate
was found to reduce the incidence of coronary events in
young male survivors of myocardial infarction participating
in the Bezafibrate Coronary Artherosclerosis Intervention
Trial (BECAIT) [20] and to reduce the combined incidence
of probable ischemic changes on resting electrocardiogram
and documented myocardial infarction in individuals with
type 2 diabetes free of clinical cardiovascular disease who
were enrolled in the St. Mary"s, Ealing, Northwick Park
Diabetes Cardiovascular Disease Prevention (SENDCAP)
study [21]. Moreover, our results may partially explain why
in the Bezafibrate Intervention Prevention study, the most
evident clinical benefits (a reduction in the primary
endpoint by 39.5%) were observed in patients with elevated
(>200 mg/dL) plasma triglyceride levels [4, 22]. Interest-
ingly, the clinical benefits of bezafibrate have been better
documented than those of fenofibrate [23, 24], although the
latter drug is more commonly used in clinical practice [7].
It is worth mentioning that in our previous study [10],
fenofibrate only insignificantly reduced lymphocyte cytokine
release in subjects with increased circulating levels of both
triglycerides and cholesterol. This clinical superiority of
bezafibrate may be attributed to its additional action on other
(β/δ and γ) types of PPARs [25, 26].
As our results show, a fibrate-induced reduction in
plasma hsCRP, also observed previously by other authors
[18, 27, 28], partially results from a decrease in lymphocyte
cytokine release. A lymphocyte-suppressing effect may be
also responsible for a fibrate-induced decrease in the
Assay results Treatment groups
Placebo Omega-3 fatty acids Bezafibrate
hsCRP (mg/L)
Baseline 3.1±0.3 3.3±0.5 3.3±0.4
Before randomization 3.0±0.4 3.1±0.4 3.2±0.3
After 4 weeks of treatment 3.2±0.5 2.6±0.4 2.2±0.2
###***
After 12 weeks of treatment 2.9±0.5 2.5±0.4 1.3±0.2
###***^^^
$$$
Interleukin-2 release (ng/mL)
Baseline 5.5±0.4 5.9±0.8 5.7±0.6
Before randomization 5.6±0.6 5.5±1.1 5.8±0.8
After 4 weeks of treatment 5.7±0.8 4.6±0.5 4.2±0.6
##**
After 12 weeks of treatment 5.8±0.8 4.5±0.8 2.8±0.4
###***^^^
$$$
Interferon-γ release (ng/mL)
Baseline 62.2±7.1 65.2±8.0 64.1±8.2
Before randomization 65.0±8.0 64.7±8.5 63.9±7.1
After 4 weeks of treatment 65.2±7.5 53.2±6.2 48.2±7.8
#**
After 12 weeks of treatment 64.8±9.7 52.4±5.9 34.2±7.9
###***^^^
$
TNF-α release (pg/mL)
Baseline 400.1±42.5 398.1±45.2 402.3±38.5
Before randomization 395.7±38.1 395.2±37.2 395.3±36.4
After 4 weeks of treatment 394.2±40.1 320.1±31.5 302.2±28.5
#*
After 12 weeks of treatment 404.3±38.4 318.6±29.2 243.1±22.5
###***^^^
$$
Table 3 The effect on bezafi-
brate and omega-3 fatty acids on
plasma C-reactive protein and
lymphocyte cytokine release in
hypertriglyceridemic patients
a
Significance levels:
#p<0.05,
##p<0.01,
###p<0.001 vs.
respective value before random-
ization. *p<0.05, **p<0.01,
***p<0.001 vs. placebo-treated
patients.^^^p<0.001 vs.
omega-3 fatty acid-treated
patients.
$p<0.05,
$$p<0.01,
$$$p<0.001 vs.
respective value after 4 weeks of
treatment
Data represent the mean±SD
a Only data of patients who
completed the study were
included in the final analyses
1114 Eur J Clin Pharmacol (2011) 67:1109–1117plasma content of TNF-α and IL-6, which was accompa-
nied by a decrease in plasma fibrinogen, in hypertriglyceri-
demic patients with concomitant mild or moderate
hypertension and in severe cardiovascular disease-free
hypertriglyceridemic patients receiving fibrate therapy [18,
27]. These findings provide evidence that inhibition of the
lymphocyte secretory function contributes to the systemic
anti-inflammatory actions of bezafibrate. Interestingly, in
our unpublished observations, the extent of a bezafibrate-
induced reduction in hsCRP in hypertriglyceridemic
patients correlated with the effect of this agent on monocyte
cytokine release (Krysiak et al., submitted), indicating that
the global anti-inflammatory impact of bezafibrate is
secondary to its action on various types of cells present in
atherosclerotic lessons. Our results have shown that the
lymphocyte-suppressing and systemic anti-inflammatory
actions of bezafibrate increased with time, and this fact
may explain a time-dependent reduction in the incidence of
the primary endpoint in bezafibrate-treated coronary artery
disease patients [22].
In addition to reducing lymphocyte cytokine release,
bezafibrate exhibited a beneficial, although weak effect on
glucose metabolism, increasing insulin sensitivity and
slightly reducing post-glucose load plasma glucose. This
finding is in agreement with our previous observations,
which revealed that fenofibrate improved glucose metabolism
markers in type 2 diabetic patients [29]; more recently, it has
also been shown to improve glucose metabolism markers in
Table 4 Effect of bezafibrate and omega-3 fatty acids on the HOMA, plasma hsCRP and lymphocyte cytokine release in insulin-sensitive and
insulin-resistant patients with isolated hypertriglyceridemia
a
Assay results Omega-3 fatty acid-treated patients Bezafibrate-treated patients
Insulin-sensitive
subjects (n=15)
Insulin-resistant
subjects (n=19)
Insulin-sensitive
subjects (n=17)
Insulin-resistant
subjects (n=18)
HOMA
Baseline 1.4±0.3 5.2±0.6*** 1.5±0.2 5.9±0.5***
Before randomization 1.3±0.2 5.1±0.5*** 1.6±0.2 5.8±0.4***
After 4 weeks of treatment 1.3±0.2 (−0.2) 5.6±0.6 (+9.8)*** 1.4±0.3 4.5±0.3 (−22.4)***
#
After 12 weeks of treatment 1.4±0.2 (−7.7) 5.2±0.4 (+2.0)*** 1.3±0.2 2.5±0.3 (−56.9)***
###$$$^^^
hsCRP (mg/L)
Baseline 2.9±0.3 3.6±0.5 2.9±0.3 3.7±0.6
Before randomization 2.8±0.4 3.3±0.4 2.6±0.4 3.8±0.5
After 4 weeks of treatment 2.3±0.3 (−17.8) 2.8±0.3 (−22.2) 2.1±0.2 (−19.2) 2.3±0.3 (−39.5)
###
After 12 weeks of treatment 2.2±0.3 (−21.4) 2.8±0.4 (−22.2) 1.6±0.2 (−38.4)
## 1.0±0.3 (−73.6)*
###$$$^^^
Interleukin-2 release (ng/mL)
Baseline 4.6±0.5 6.9±0.8*** 4.5±0.7 6.8±0.4***
Before randomization 4.3±0.5 6.5±0.7*** 4.4±0.5 7.0±0.7***
After 4 weeks of treatment 3.8±0.5 (−11.6) 5.3±0.6 (−18.5)*** 3.4±0.5 (−22.7)
# 5.0±0.7 (−28.6)***
##
After 12 weeks of treatment 3.7±0.4 (−14.0) 5.2±0.5 (−19.8)*** 3.1±0.6 (−29.5)
## 2.5±0.4 (−64.3)
###$$$^^^
Interferon-γ release (ng/mL)
Baseline 54.3±7.8 73.8±6.4*** 53.1±6.2 74.5±7.4***
Before randomization 53.2±7.5 73.7±8.3*** 52.8±7.3 74.3±6.9***
After 4 weeks of treatment 43.1±5.8 (−19.0) 61.2±6.5 (−17.0)*** 41.3±5.7 (−21.8)
# 54.7±5.0 (−26.4)**
##
After 12 weeks of treatment 42.9±6.5 (−19.4) 59.9±6.8 (−18.7)*** 38.4±8.0 (−27.3)
# 30.1±5.3 (−59.5)
###$$$^^^
TNF-α release (pg/mL)
Baseline 338.5±34.4 445.1±40.4** 345.9±30.2 458.6±40.2***
Before randomization 337.4±32.1 440.8±35.6** 340.2±31.1 455.6±41.7***
After 4 weeks of treatment 274.3±25.1 (−18.7) 356.2±50.2 (−19.2)** 274.5±29.1 (−19.3) 328.4±35.5 (−27.3)
##
After 12 weeks of treatment 273.9±30.5 (−18.8) 353.8±40.7 (−19.7)** 259.8±25.3 (−23.6)
# 225.9±41.2 (−50.4)
###$$^^^
*p<0.05, **p <0.01, ***p<0.001 vs. insulin-sensitive patients in the same treatment group;
#p<0.05,
##p<0.01,
###p<0.001 vs. respective value
before randomization;
$$p<0.01,
$$$p<0.001 indicate that the effect was stronger than after the 4-week treatment; p<0.001 indicates the effect of
bezafibrate at the end of the study was stronger than the effect of omega-3 fatty acids in the same subgroup of patients
Each value represents the mean±SD. Values in parenthesis represent the percentage change from the respective values on the day of randomization
aOnly data of patients who completed the study were included in the final analyses
Eur J Clin Pharmacol (2011) 67:1109–1117 1115subjects with prediabetes [30]. Because the effect on the
HOMA and post-challenge plasma glucose was exhibited by
two drugs that differ from each other in their physicochemical
and pharmacokinetic properties [25, 26], this effect likely
represents a “class effect” of fibrates and may explain why
bezafibrate treatment reduced the incidence of diabetes by
30% in subjects with a baseline glucose level between 110
and 125 mg/dl [22].
Incomparisonwithbezafibrate,theeffect ofomega-3fatty
acids was much more limited, and in the case of cytokine
releaseandplasmahsCRP,theeffectdidnotreachthelevelof
statistical significance. This finding is in agreement with the
results of a meta-analysis of randomized controlled trials,
which showed only small changes in plasma hsCRP in
patients treated with omega-3 fatty acids [31]. Taking into
consideration the role of both lymphocytes and proinflam-
matory cytokines in the process of atherogenesis [8, 9, 13,
15], a weak lymphocyte-suppressing effect of omega-3 fatty
acids may be, however, clinically relevant. It may have
contributed to a reduction in the number of coronary artery
disease events found in the Japan EPA Lipid Intervention
Study (JELIS) [32] and to a reduction in the number of
deaths from any cause, nonfatal myocardial infarction and
nonfatal stroke observed in the Gruppo Italiano per lo Studio
della Sopravvivenza nell"Infarto (GISSI)-Prevenzione trial
[33]. However, it may be too weak to prevent the incidence
of sudden cardiac death, fatal and nonfatal myocardial
infarction, coronary artery bypass grafting and percutaneous
coronary interventions [32]. Unlike bezafibrate, the effect of
omega-3 fatty acids on lymphocyte cytokine release and
systemic inflammation was almost maximal after only
4 weeks of treatment, which may in part explain why in
the GISSI-Prevenzione trial benefits of omega-3 fatty acid
therapy appeared shortly after its initiation [33]. Because
omega-3 fatty acids did not affect glucose homeostasis
markers while the anti-inflammatory effect did not differ
between “insulin-sensitive” and “insulin-resistant” subjects,
it seems that their administration brings similar clinical
benefits to patients with and without glucose metabolism
abnormalities.
The lack of correlation between the extent of the reduction
in lipid levels and the effect of hypolipemic treatment on T
lymphocyte function indicates that the observed changes in
inflammatory mediators cannot be explained by triglyceride-
lowering or other lipid- modulating features of the two agents
investigated and that the latter represent pleiotropic effects.
Lymphocyte-suppressing and global anti-inflammatory effects
of bezafibrate correlated with the degree of reduction in the
HOMA. Moreover, these effects were stronger in “insulin-
resistant” than in “insulin-sensitive” subjects. This finding is in
agreementwiththeresultsofthe VeteransAffairsHigh-Density
Lipoprotein Intervention Trial (VA-HIT), which revealed that
gemfibrozil reduced cardiovascular events and cardiovascular
mortality mainly in type 2 diabetic subjects or in nondiabetic
patients with elevated plasma insulin [34]. One of the factors
linking the restoration of insulin sensitivity and lymphocyte-
suppressing and CRP-lowering effects of bezafibrate are free
fatty acids, which are the endogenous ligands for PPAR [35].
We make this assumption because in our previous observa-
tions [36], fenofibrate action on monocyte secretory function
and plasma hsCRP correlated with a fenofibrate-induced
reduction in the circulating levels of free fatty acids. In turn,
omega-3 fatty acids may produce their weak lymphocyte-
suppressive and systemic anti-inflammatory effects indirectly
bydisplacing omega-6 fatty acids, including arachidonic acid,
in the cell membrane and reducing the production of other
proinflammatoryfactors,includingprostaglandins,thrombox-
anes and leukotrienes [37].
Thisstudy isnot free ofa numberoflimitations.Firstly, we
recruited a relatively small number of participants. It is
possible that the effect of omega-3 fatty acids would reach
the level of statistical significance if more patients were
included. Secondly, patients were treated with moderatedoses
of either bezafibrate or omega-3 fatty acids. Therefore, we
cannot exclude that these agents, particularly omega-3 fatty
acids, produce even stronger lymphocyte-suppressing and
systemic anti-inflammatory effects if they are administered at
higher doses or in combination. Finally, as we assessed global
secretory function of lymphocytes, there may be some
differences between various subsets of Tcells with respect to
their response to bezafibrate and omega-3 fatty acids.
To summarize, this study has shown that bezafibrate
produces both lipid-improving and anti-inflammatory
effects in hypertriglyceridemic subjects, while the analog
effects of low dose omega-3 fatty acids are much more
moderate. Our findings indicate that bezafibrate is superior
to omega-3 fatty acids in inhibiting systemic inflammation
and lymphocyte secretory function.
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